Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy, Conformal | 11 | 2004 | 902 | 0.390 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 966 | 0.160 |
Why?
|
| Prostatic Neoplasms | 8 | 2004 | 5767 | 0.130 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 76 | 0.130 |
Why?
|
| Scoliosis | 1 | 2016 | 139 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1429 | 0.120 |
Why?
|
| Brain Neoplasms | 4 | 2004 | 4849 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.110 |
Why?
|
| Immobilization | 2 | 2002 | 93 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2016 | 1144 | 0.100 |
Why?
|
| Xerostomia | 2 | 2003 | 190 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 1450 | 0.090 |
Why?
|
| HIV Infections | 1 | 2003 | 2134 | 0.090 |
Why?
|
| Rectum | 2 | 2002 | 467 | 0.090 |
Why?
|
| Catheterization | 2 | 2002 | 410 | 0.090 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2007 | 126 | 0.080 |
Why?
|
| Gene Expression | 1 | 2016 | 3570 | 0.080 |
Why?
|
| Radiation Injuries | 3 | 2004 | 1411 | 0.070 |
Why?
|
| Parotid Gland | 2 | 2003 | 112 | 0.070 |
Why?
|
| Depression | 1 | 2016 | 1715 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2004 | 2370 | 0.070 |
Why?
|
| Genetic Therapy | 2 | 2004 | 1616 | 0.060 |
Why?
|
| Acyclovir | 1 | 2004 | 78 | 0.060 |
Why?
|
| Thymidine Kinase | 1 | 2004 | 193 | 0.060 |
Why?
|
| Valine | 1 | 2004 | 176 | 0.060 |
Why?
|
| Homosexuality | 1 | 2003 | 32 | 0.060 |
Why?
|
| Reed-Sternberg Cells | 1 | 2003 | 44 | 0.060 |
Why?
|
| Radiometry | 3 | 2003 | 980 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 3 | 2003 | 3976 | 0.060 |
Why?
|
| Hearing | 1 | 2002 | 64 | 0.050 |
Why?
|
| Vinblastine | 1 | 2003 | 453 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 305 | 0.050 |
Why?
|
| Bleomycin | 1 | 2003 | 467 | 0.050 |
Why?
|
| Trigeminal Neuralgia | 1 | 2002 | 42 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2004 | 323 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 2003 | 203 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2002 | 159 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2003 | 317 | 0.050 |
Why?
|
| Prostatectomy | 2 | 2003 | 962 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2003 | 485 | 0.050 |
Why?
|
| Radiotherapy Dosage | 6 | 2004 | 3842 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 829 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 993 | 0.050 |
Why?
|
| Meningioma | 1 | 2002 | 289 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 1415 | 0.040 |
Why?
|
| Male | 18 | 2016 | 123000 | 0.040 |
Why?
|
| Biopsy | 2 | 2004 | 3443 | 0.040 |
Why?
|
| Multiple Sclerosis | 1 | 2002 | 349 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2002 | 434 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 14889 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2003 | 726 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2002 | 540 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2002 | 529 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2004 | 10035 | 0.040 |
Why?
|
| Adult | 11 | 2016 | 77950 | 0.040 |
Why?
|
| Aged | 13 | 2016 | 70117 | 0.040 |
Why?
|
| Taiwan | 1 | 2016 | 93 | 0.030 |
Why?
|
| Middle Aged | 14 | 2016 | 86204 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2003 | 3005 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 172 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2006 | 2967 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2003 | 7551 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 7789 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2006 | 13658 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 1099 | 0.030 |
Why?
|
| Humans | 20 | 2016 | 261506 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2004 | 1797 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 1489 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2002 | 1330 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 7548 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2016 | 16273 | 0.030 |
Why?
|
| Combined Modality Therapy | 4 | 2004 | 8865 | 0.020 |
Why?
|
| Female | 11 | 2016 | 141928 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 2437 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2004 | 2292 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4109 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2004 | 1459 | 0.020 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2007 | 29902 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2016 | 37905 | 0.020 |
Why?
|
| Child | 4 | 2016 | 29154 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7702 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2006 | 115 | 0.020 |
Why?
|
| Antiviral Agents | 2 | 2004 | 1230 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13310 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 660 | 0.020 |
Why?
|
| Flutamide | 1 | 2004 | 40 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.010 |
Why?
|
| Leuprolide | 1 | 2004 | 65 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2003 | 15862 | 0.010 |
Why?
|
| Thirst | 1 | 2003 | 7 | 0.010 |
Why?
|
| Salivation | 1 | 2003 | 20 | 0.010 |
Why?
|
| Dysgeusia | 1 | 2003 | 7 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 9244 | 0.010 |
Why?
|
| Speech Disorders | 1 | 2003 | 91 | 0.010 |
Why?
|
| Prodrugs | 1 | 2004 | 217 | 0.010 |
Why?
|
| Audiometry | 1 | 2002 | 24 | 0.010 |
Why?
|
| Penile Erection | 1 | 2002 | 86 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 15694 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2002 | 174 | 0.010 |
Why?
|
| Androgen Antagonists | 1 | 2004 | 411 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 15193 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 5687 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 1301 | 0.010 |
Why?
|
| Morbidity | 1 | 2002 | 397 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 1290 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2003 | 348 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 447 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 840 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 17523 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2004 | 1694 | 0.010 |
Why?
|
| Prostate | 1 | 2004 | 1088 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2002 | 629 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 2203 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 573 | 0.010 |
Why?
|
| Time Factors | 2 | 2002 | 12926 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 2803 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 21445 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 1033 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2003 | 3981 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 5395 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 9180 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 5112 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 12873 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2002 | 32848 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 6942 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 10001 | 0.010 |
Why?
|
| Quality of Life | 1 | 2002 | 4532 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 34495 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 11538 | 0.000 |
Why?
|
| Animals | 1 | 2002 | 59536 | 0.000 |
Why?
|